Oral insulin (human, murine, or porcine) does not prevent diabetes in the non-obese diabetic mouse

Clinical Immunology

Volumn 164, Issue , 2016, Pages 28-33

  Pham, Minh N ^a   Gibson, Claire ^a   Rydén, Anna K E ^a   Perdue, Nikole ^a   Boursalian, Tamar E ^a   Pagni, Philippe P ^a,c   Coppieters, Ken ^b   Skonberg, Christian ^b   Porsgaard, Trine ^b   von Herrath, Matthias ^a,c   Vela, Jose Luis ^a  

^a NOVO NORDISK INC   (United States)

^b NOVO NORDISK A S   (Denmark)

^c LA JOLLA INSTITUTE FOR ALLERGY AND IMMUNOLOGY   (United States)

Author keywords

Insulin; Mouse models; NOD; Oral tolerance; Type 1 diabetes

Indexed keywords

ANTIDIABETIC AGENT; ANTIGEN; GLUCOSE BLOOD LEVEL; HEMOCYANIN; INSULIN; KEYHOLE-LIMPET HEMOCYANIN;

ANALYSIS; ANIMAL; BAGG ALBINO MOUSE; BLOOD; C57BL MOUSE; DELAYED HYPERSENSITIVITY; DIABETES MELLITUS, EXPERIMENTAL; DIABETES MELLITUS, TYPE 1; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; IMMUNOLOGICAL TOLERANCE; IMMUNOLOGY; INTESTINE; MALE; METABOLISM; NONOBESE DIABETIC MOUSE; ORAL DRUG ADMINISTRATION; PIG;

ADMINISTRATION, ORAL; ANIMALS; ANTIGENS; BLOOD GLUCOSE; DIABETES MELLITUS, EXPERIMENTAL; DIABETES MELLITUS, TYPE 1; FEMALE; HEMOCYANIN; HUMANS; HYPERSENSITIVITY, DELAYED; HYPOGLYCEMIC AGENTS; IMMUNE TOLERANCE; INSULIN; INTESTINES; MALE; MICE, INBRED BALB C; MICE, INBRED C57BL; MICE, INBRED NOD; SWINE;

EID: 84955596980     PISSN: 15216616     EISSN: 15217035     Source Type: Journal    
DOI: 10.1016/j.clim.2016.01.013     Document Type: Article

References (21)

1. Reed J.C., Herold K.C. Thinking bedside at the bench: the NOD mouse model of T1DM. Nat. Rev. Endocrinol. 2015, 11(5):308-314.
2. Pozzilli P., Signore A., Williams A.J., Beales P.E. NOD mouse colonies around the world - recent facts and figures. Immunol. Today 1993, 14(5):193-196.
3. Benson J.M., Campbell K.A., Guan Z., et al. T-cell activation and receptor downmodulation precede deletion induced by mucosally administered antigen. J. Clin. Invest. 2000, 106(8):1031-1038.
4. Faria A.M., Weiner H.L. Oral tolerance: therapeutic implications for autoimmune diseases. Clin. Dev. Immunol. 2006, 13(2-4):143-157.
5. Zhang Z.J., Davidson L., Eisenbarth G., Weiner H.L. Suppression of diabetes in nonobese diabetic mice by oral administration of porcine insulin. Proc. Natl. Acad. Sci. U. S. A. 1991, 88(22):10252-10256.
6. Homann D., Dyrberg T., Petersen J., Oldstone M.B., von Herrath M.G. Insulin in oral immune "tolerance": a one-amino acid change in the B chain makes the difference. J. Immunol. 1999, 163(4):1833-1838.
7. Karounos D.G., Bryson J.S., Cohen D.A. Metabolically inactive insulin analog prevents type I diabetes in prediabetic NOD mice. J. Clin. Invest. 1997, 100(6):1344-1348.
8. Skyler J.S., Krischer J.P., Wolfsdorf J., et al. Effects of oral insulin in relatives of patients with type 1 diabetes: the Diabetes Prevention Trial - Type 1. Diabetes Care 2005, 28(5):1068-1076.
9. Bonifacio E., Ziegler A.G., Klingensmith G., et al. Effects of high-dose oral insulin on immune responses in children at high risk for type 1 diabetes: the Pre-POINT randomized clinical trial. JAMA 2015, 313(15):1541-1549.
10. Pozzilli P., Pitocco D., Visalli N., et al. No effect of oral insulin on residual beta-cell function in recent-onset type I diabetes (the IMDIAB VII). IMDIAB Group. Diabetologia 2000, 43(8):1000-1004.
11. Lernmark A., Larsson H.E. Immune therapy in type 1 diabetes mellitus. Nat. Rev. Endocrinol. 2013, 9(2):92-103.
12. Barker J.M., McFann K.K., Orban T. Effect of oral insulin on insulin autoantibody levels in the Diabetes Prevention Trial Type 1 oral insulin study. Diabetologia 2007, 50(8):1603-1606.
13. Bregenholt S., Wang M., Zdravkovic M., Dyrberg T., Petersen J.S. A new model for analyzing immunomodulation of T cell responses induced by oral administration of islet cell antigens. Ann. N. Y. Acad. Sci. 2002, 958:179-181.
14. Tang Q., Bluestone J.A. Regulatory T-cell physiology and application to treat autoimmunity. Immunol. Rev. 2006, 212:217-237.
15. Gill R.G., Pagni P.P., Kupfer T., et al. A preclinical consortium approach for assessing the efficacy of cobined anti-CD3 plus IL-1 blocakde reversing new-onset autoimmune diabetes in NOD mice. Diabetes 2015, [Epub ahead of print].
16. Incidence studies. 2015. 13-7-2015.
17. Grant C.W., Moran-Paul C.M., Duclos S.K., Guberski D.L., Arreaza-Rubin G., Spain L.M. Testing agents for prevention or reversal of type 1 diabetes in rodents. PLoS One 2013, 8(8).
18. Toren P., Smith D., Chance R., Hoffman J. Determination of interchain crosslinkages in insulin B-chain dimers by fast atom bombardment mass spectrometry. Anal. Biochem. 1988, 169(2):287-299.
19. Schilling R.J., Mitra A.K. Degradation of insulin by trypsin and alpha-chymotrypsin. Pharm. Res. 1991, 8(6):721-727.
20. Burks A.W., Jones S.M., Wood R.A., et al. Oral immunotherapy for treatment of egg allergy in children. N. Engl. J. Med. 2012, 367(3):233-243.
21. Du T.G., Roberts G., Sayre P.H., et al. Randomized trial of peanut consumption in infants at risk for peanut allergy. N. Engl. J. Med. 2015, 372(9):803-813.